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Abstract
Canine babesiosis is an important worldwide, tick-borne disease caused by hemoprotozoan parasites of the genus 
Babesia. Babesia gibsoni is the predominant species that causes canine babesiosis in Taipei, Taiwan. It is a small 
pleomorphic intraerythrocytic parasite that can cause erythrocyte destruction and hemolytic anemia. Efficacy of oral 
administration of a doxycycline-enrofloxacin-metronidazole combination with and without injections of diminazene 
diaceturate in the management of naturally occurring canine babesiosis caused by B. gibsoni was evaluated 
retrospectively. The overall efficacy of this combination of doxycycline-enrofloxacin-metronidazole in conjunction with 
and without administration of diminazene diaceturate was 85.7% and 83.3%, respectively; with a mean recovery time 
of 24.2 and 23.5 days, respectively. Concomitant use of intramuscular diminazene diaceturate may not improve the 
efficacy of a doxycycline-enrofloxacin-metronidazole combination in management of canine babesiosis caused by B. 
gibsoni.
Findings
Canine babesiosis is an important worldwide, tick-borne
disease caused by hemoprotozoan parasites of the genus
Babesia, and the predominant species infecting dogs is B.
vogeli [1]. In a previous study, B. gibsoni was found to be
the major causative agent of canine babesiosis in Taipei,
Taiwan [2]. Babesia gibsoni is a small pleomorphic, intra-
erythrocytic parasite that can cause erythrocyte destruc-
tion and hemolytic anemia [1]. This parasite is suspected
to be transmitted through the bite of ixodid ticks, such as
Rhipicephalus sanguineus [1,3-8].
Clinical signs of canine babesiosis are characterized by
lethargy, anorexia, fever, hemolytic anemia, thrombocy-
topenia, splenomegaly and even septic shock [2,9-14].
Chronic infection is common. Definitive diagnosis of
canine babesiosis is based on medical history and clinical
signs together with the identification of Babesia  spp.
within infected erythrocytes, positive serologic results,
and detection of amplification of nucleic acid extracted
from blood or tissues [4,5,15].
Many drugs have been applied in management of
canine babesiosis, including babesiacidal agents (dimina-
zene aceturate, imidocarb diproprionate), antibiotics
(azithromycin, clindamycin, doxycycline, metronidazole),
and an antiprotozoal agent (Atovaquone). However, no
single drug has successfully eliminated B. gibsoni from
infected dogs [9,10,12,13,15-18]. Addictive or synergistic
effects of these drugs in combination have not been fully
evaluated. The babesiacide diminazene diaceturate is
mainly used in horses, donkeys and cows [19-21]. Effi-
cacy of diminazene diaceturate in management of canine
babesiosis is limited, but this is the only diminazene avail-
able for veterinary use in Taiwan, whereas atovaquone is
not yet available. The aim of this study was to evaluate the
efficacy of a doxycycline-enrofloxacin-metronidazole (D-
E-M) combination with and without administration of
diminazene diaceturate to manage naturally occurring
canine babesiosis caused by B. gibsoni.
Medical records of dogs in which babesiosis was diag-
nosed at the National Taiwan University Veterinary Hos-
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pital from January 2005 to December 2006 were
reviewed. Inclusion criteria were history of tick infesta-
tion, presence of anemia, and identification of B. gibsoni
in the stained blood films, and treatment with an oral
doxycycline (7-10 mg/Kg, q 12 hours; China Chemical &
Pharmaceutical Co. Ltd., Taipei, Taiwan)-enrofloxacin (2-
2.5 mg/Kg, q 12 hours; Baytril®, Bayer HealthCare AG,
Leverkusen, Germany)-metronidazole (5-15 mg/Kg, q 12
hours; Sinphar Pharmaceutical Co. Ltd. Taipei, Taiwan;
D-E-M) combination of six weeks with and without two
intramuscular injections of diminazene diaceturate (3
mg/Kg, q 7 days; Tricip Plus®, Cipla Ltd., Mumbai, India).
Informed consent of using diminazene diaceturate had
been obtained from the owners of dogs. Breed, sex, age,
pre-treatment complete cell counts, bi-weekly follow-up
complete cell counts, and the outcome for each case were
recorded. Co-infection with other tick-borne diseases,
such as Anaplasma phagocytophilum and Ehrlichia canis
were excluded using a commercially available immunoen-
zymatic dot-ELISA assays (Snap 4Dx, Idexx Laboratories
Inc., Maine, U.S.A.).
In this study, identification of B. gibsoni was based on
morphological characteristics of intraerythrocytic para-
sites found in the stained blood films. Dogs affected with
other babesia species, such as B. canis and B. vogeli were
excluded from this study. Efficacy of treatment was
defined as elimination of B. gibsoni in blood films, and
clinical remission for seven weeks after the treatment was
discontinued.
Comparison of the time to reach clinical remission
between two treatment protocols was performed by
means of repeated-measures ANOVAs. Associations
between sex, age, treatment protocols, and time to reach
clinical remission were evaluated by means of ANOVA.
Variables that might have influenced relapse of anemia
and persistent parasitemia were analyzed by use of a Cox
proportional hazard model. Such variables included sex,
age and severity of anemia at diagnosis, and treatment
protocol. Data for dogs that failed to response (relapse of
anemia and persistent parasitemia) were censored. All
statistical analyses were performed using SPSS software
(Statistical Package for the Social Sciences, version 13.0;
SSPS Inc, Illinois, USA). Continuous data are presented
as mean ± SD. Statistical significance was set at P ≤ 0.05.
Medical records of 6789 dogs from January 2005 to
December 2006 were screened. Of these, 118 cases was
diagnosed as babesiosis and caused by B. gibsoni. Breeds
of the 40 dogs included in this study were: 10 Maltese ter-
riers; four each of Beagles, mixed breeds and miniature
Schnauzers; three of Labrador retrievers and Yorkshire
terriers; two each of Pit bull terriers, Golden retrievers,
and Pomeranians; one each of Chihuahua, Siberian
Husky, Old English sheepdog, miniature Poodle, Pug and
Shih Tzu. The mean age of the dogs included in the study
was 5.3 ± 3.9 years, and ranged from 9 months to 14 years
old. The ratio of male to female was 3 to 1.
Twenty-eight dogs were treated with an oral combina-
tion of D-E-M for six weeks plus two intramuscular injec-
tions of diminazene diaceturate, whereas 12 dogs
received only the oral combination of D-E-M for six
weeks.
Of 28 dogs (mean age: 6.0 ± 3.8 years) treated with oral
D-E-M combination and two intramuscular injections of
diminazene diaceturate, 4 dogs showed relapse of anemia
and parasitemia after 14, 28, 35 and 42 days, respectively,
and 24 dogs had clinical remission. The overall efficacy of
multiple antibiotics combined with diminazene diacetu-
rate was 85.7%, with a mean recovery time of 24.2 days (n
= 24, Table 1).
Of 12 dogs (mean age: 3.6 ± 3.8 years) treated with D-E-
M, but were not given injections of diminazene diacetu-
rate relapsed anemia was identified in 2 dogs after 45 and
73 days, while another 10 dogs reached clinical remission.
The overall efficacy of management of canine babesiosis
using only multiple antibiotics was 83.3%, with a mean
recovery time of 23.5 days (n = 10, Table 2).
No significant difference was seen in management effi-
cacy between the two protocols (P = 0.36). The time to
reach clinical remission was not affected by sex, age or
treatment protocols (P = 0.88, P = 0.36, P = 0.38, respec-
tively).
Results of the Cox proportional hazard model indicated
that relapse of anemia and persistent parasitemia was not
associated with sex, age or severity of anemia at diagno-
Table 1: Hematological parameters (mean and standard deviation, SD) in 24 dogs showing clinical remission for 
babesiosis following treatment with a doxycycline-enrofloxacin-metronidazole combination and intramuscular 
diminazene diaceturate.
Parameter Reference Range Day 0
Mean (SD)
Day 14
Mean (SD)
Day 28
Mean (SD)
Day 90
Mean (SD)
RBC (×106/μL) 5.2-7.9 2.7 (1.7) 3.7 (1.6) 5.3 (1.1) 5.8 (0.5)
Hb (g/dL) 11.6-17.1 6.8 (4.7) 8.2 (3.8) 11.5 (1.5) 12.2 (0.8)
Hct (%) 38.4-53.1 21.5 (10.3) 29.3 (7.4) 34.7 (6.9) 38.2 (4.8)
RBC, red blood cell count; Hb haemoglobin; Hct: haematocrit.Lin and Huang Acta Veterinaria Scandinavica 2010, 52:27
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sis, or treatment protocol (P = 0.72, P = 0.72, P = 0.65, P =
0.52, respectively)
In this study, the overall prevalence of canine babesiosis
caused by B. gibsoni was 1.7%, which was only slightly
higher than the prevalence established in a similar study
conducted 10 years earlier (1.6%) [2].
In our previous study, Maltese terriers seemed to be
predisposed to babesiosis [2]. In the present study, the
Maltese terrier was accounting for 25% of the cases of
babesiosis, but no further statistical analyses were carried
out to assert that Maltese terrier was predisposing to
canine babesiosis. Maltese terrier is, however, much less
popular compared to 10 years ago. A large scale study of
breed predisposition to this disease is warranted. Certain
breeds, such as American Pit Bull terriers and Tosa dogs
[5,22], have also been found to having higher rates of sub-
clinical infection with B. gibsoni. Particularly dogs that
have been bitten were found to have a higher subclinical
infection with B. gibsoni [5,22,23].
The efficacy of treatment of babesiosis caused by B. gib-
soni with either doxycycline or metronidazole has been
evaluated, but the ability of each drug alone to success-
fully treat B. gibsoni is still controversial [18]. In the pres-
ent study, synergistic efficacy of the D-E-M combination
was 83.3%. Relapse of anemia and persistent parasitemia
was not associated with sex, age or severity of anemia at
diagnosis, or D-E-M combination with or without dimi-
nazene diaceturate.
Diminazene aceturate, an aromatic diamidine com-
pound, can interfere with the synthesis of DNA and aero-
bic glycolysis and has been commonly used against
infection of canine babesiosis caused by B. gibsoni [18].
Diminazene diaceturate has also been widely used against
infection of babesiosis in horses, donkeys and cows
[13,20,21]. In a comparative study, diminazene aceturate
exhibited a higher efficacy than diminazene diaceturate
in the treatment of babesiosis in horses [21]. In the pres-
ent study, efficacy and the time to achieve clinical remis-
sion did not differ between the two treatment protocols.
Although the efficacy of the administration of dimina-
zene diaceturate alone against B. gibsoni was not evalu-
ated in our study, it suggested that concomitant use of
diminazene diaceturate may not improve the efficacy of a
D-E-M combination treatment of canine babesiosis
caused by B. gibsoni.
All cases of subclinical infection of B. gibsoni may not
be detected solely by, morphological identification in
blood smears, and polymerase chain reaction assay
should therefore be included in further studies in order to
identify subclinical carriers after treatment.
Concomitant use of intramuscular diminazene diacetu-
rate may not improve the efficacy of a doxycycline-enro-
floxacin-metronidazole combination in management of
canine babesiosis caused by B. gibsoni.
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